[Swiftwater Gazette] antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Ed kroposki kroposki at att.net
Wed Aug 31 15:17:11 EDT 2016

Theantibody aducanumab reduces Aβ plaques inAlzheimer’s disease
Alzheimer’sdisease (AD) is characterized by deposition of amyloid-β (Aβ) 
plaques and neurofibrillary tangles in the brain, accompanied bysynaptic 
dysfunction and neurodegeneration. Antibody-basedimmunotherapy 
against Aβ to trigger its clearance or mitigate itsneurotoxicity has so far 
been unsuccessful. Here we report thegeneration of aducanumab, a 
human monoclonal antibody thatselectively targets aggregated Aβ.
Resultsjustify further development of aducanumab for the treatment 
of AD.Should the slowing of clinical decline be confirmed in ongoing 
phase3 clinical trials, it would provide compelling support for the 
amyloid hypothesis.


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mailman.theswiftwatergazette.com/pipermail/swiftwatergazette/attachments/20160831/d5665c61/attachment.html>

More information about the SwiftwaterGazette mailing list